Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

oriola rīga, sia 50003199991 dzelzavas ielā 120m, rīga, lv-1021 - pulveris - cits - diētiskā pārtika cilvēkiem ar veselības traucējumiem. diētiskai lietošanai ar fenilketonūriju slimojošiem bērniem no 8 gadu vecuma un pieaugušajiem, t.sk. grūtniecēm.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

oriola rīga, sia 50003199991 dzelzavas ielā 120m, rīga, lv-1021 - pulveris - cits - diētiskā pārtika cilvēkiem ar veselības traucējumiem. diētiskai lietošanai ar fenilketonūriju slimojošiem bērniem no 8 gadu vecuma un pieaugušajiem, t.sk. grūtniecēm.

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

oriola rīga, sia 50003199991 dzelzavas ielā 120m, rīga, lv-1021 - pulveris - cits - diētiskā pārtika cilvēkiem ar veselības traucējumiem. diētiskai lietošanai ar fenilketonūriju slimojošiem pacientiem - zīdaiņu uzturam (no dzimšanas līdz 12 mēnešiem) un papildu ēdināšanai bērniem līdz 3 gadu vecumam.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

nova laboratories ireland limited - azatioprīns - transplanta noraidīšana - imūnsupresanti - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - imūnsupresanti - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Latvija - latviešu - Pārtikas un veterinārais dienests, Zemkopības ministrija

sia “nutricia” 40103070928 gustava zemgala gatve 74, rīga, lv-1039, latvija - cits, tabletes - īpašiem medicīniskiem nolūkiem paredzēta pārtika - Īpašiem medicīniskiem nolūkiem paredzēta pārtika. uztura režīms fenilketonūrijas un līdzīgu aminoskābju vielmaiņas traucējumu gadījumos, kad nepieciešams vitamīnu, minerālvielu un mikroelementu papildinājums. tabletes satur vitamīnus, mikroelementus, kalciju, fosforu un magniju.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemophilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.